See Full Report below….
About Broad Street Alerts:
Big opportunities in Small Cap’s
Broad Street Alerts recent profiles and track record, 153% in verifiable potential gains for our
Members in the last 3 small cap alerts alone!
February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our members gains- 83%
March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.
March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49%
for our members.
These are numbers that make traders drool. Any trader in any market would fall all over themselves to
see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and
verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest
of the small-cap newsletters as the best in business. We know with a large following comes a large
responsibility as we have everyone from institutional investors to the beginner following our profiled
securities in our newsletters. This is something we take very seriously always seeking small cap growth
companies that have both near and long-term potential for our members.
***Get our small cap profiles, special situation and watch alerts in real time.
We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.
Report:
JMP Securities reissued their buy rating on shares ofIntercept Pharmaceuticals Inc (NASDAQ:ICPT) in a research note issued to investors on Wednesday,Market Beat.com reports. They currently have a $200.00 price target on the biopharmaceutical company’s stock.
Several other analysts have also recently issued reports on the company. Morgan Stanley upgraded Intercept Pharmaceuticals from an underweight rating to an equal weight rating and set a $100.00 target price for the company in a report on Friday, January 29th. Needham & Company LLC reissued a buy rating and issued a $500.00 price objective on shares of Intercept Pharmaceuticals in a report on Wednesday, January 27th. Cowen and Company restated an outperform rating and set a $212.00 price objective on shares of Intercept Pharmaceuticals in a research report on Tuesday, March 8th. Goldman Sachs began coverage on shares of Intercept Pharmaceuticals in a research note on Wednesday, March 30th. They set a neutral rating and a $114.00 target price on the stock. Finally, Barclays decreased their target price on shares of Intercept Pharmaceuticals from $300.00 to $200.00 and set an overweight rating on the stock in a report on Wednesday, February 24th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and eleven have issued a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus price target of $253.30.
In other news, insider Lisa Bright sold 241 shares of the stock in a transaction that occurred on Thursday, February 25th. The stock was sold at an average price of $115.22, for a total value of $27,768.02. Following the completion of the sale, the insider now directly owns 19,259 shares of the company’s stock, valued at $2,219,021.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
A number of hedge funds and institutional investors have modified their holdings of the company. CenturyLink Investment Management Co increased its position in shares of Intercept Pharmaceuticals by 94.6% in the fourth quarter. CenturyLink Investment Management Co now owns 2,092 shares of the biopharmaceutical company’s stock valued at $312,000 after buying an additional 1,017 shares during the last quarter. Profund Advisors LLC boosted its stake in shares of Intercept Pharmaceuticals by 0.5% in the fourth quarter. Profund Advisors LLC now owns 12,113 shares of the biopharmaceutical company’s stock worth $1,809,000 after buying an additional 65 shares during the last quarter. DekaBank Deutsche Girozentrale boosted its stake in shares of Intercept Pharmaceuticals by 1.7% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 12,310 shares of the biopharmaceutical company’s stock worth $1,847,000 after buying an additional 200 shares during the last quarter. Bellevue Asset Management AG boosted its stake in shares of Intercept Pharmaceuticals by 55.2% in the fourth quarter. Bellevue Asset Management AG now owns 13,500 shares of the biopharmaceutical company’s stock worth $2,016,000 after buying an additional 4,800 shares during the last quarter. Finally, Polar Capital LLP boosted its stake in shares of Intercept Pharmaceuticals by 3.4% in the fourth quarter. Polar Capital LLP now owns 13,921 shares of the biopharmaceutical company’s stock worth $2,079,000 after buying an additional 462 shares during the last quarter.
Intercept Pharmaceuticals (NASDAQ:ICPT) traded up 4.914% during mid-day trading on Wednesday, reaching $137.185. The company’s stock had a trading volume of 426,692 shares. Intercept Pharmaceuticals has a one year low of $89.76 and a one year high of $314.88. The company’s market capitalization is $3.34 billion. The stock has a 50-day moving average price of $121.40 and a 200-day moving average price of $147.14.
Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its earnings results on Tuesday, February 23rd. The biopharmaceutical company reported ($3.62) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($3.15) by $0.47. The firm earned $0.45 million during the quarter, compared to analyst estimates of $0.43 million. During the same quarter in the prior year, the company posted ($1.63) EPS. Intercept Pharmaceuticals’s revenue was up .4% on a year-over-year basis. Equities research analysts forecast that Intercept Pharmaceuticals will post ($15.73) EPS for the current year.
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry. The Company’s product candidate, obeticholic acid (NASDAQ:ICPT), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).
Source: IRA Market Report
Broad Street Alerts has not been compensated for the mention of _ICPT__ and we do not hold any positions.
